<DOC>
	<DOC>NCT02387762</DOC>
	<brief_summary>This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate.</brief_summary>
	<brief_title>ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Main Diagnosis of RA according to the 2010 ACR/EULAR Classification Criteria . Must be on a stable MTX dose (7.5 to 25 mg/week) Subjects must be able to read and understand the consent form, complete the studyrelated procedures, and communicate with the study staff. Are willing and able to adhere to the study visit schedule, and understand and comply with other protocol requirements. Main Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for â‰¥ 5 years. A lifethreatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ACP196, or put the study outcomes at undue risk. Subjects who have taken any investigational drug within the previous 30 days before randomization. Use of all other synthetic diseasemodifying antirheumatic drugs (DMARDS) such as but not limited to leflunomide, azathioprine, cyclosporine, penicillamine or gold salts within 8 weeks of randomization. Use of etanercept, anakinra, tofacitinib within 4 weeks of randomization. Use of abatacept, humira, infliximab, or tocilizumab within 8 weeks of randomization.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Acalabrutinib</keyword>
</DOC>